GlassScriptPhysician profile
David L Finke
NPI 1912151184
$9,950.18
in general payments reported to CMS, 2019-2025
46 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $490 · 2021: $1,515 · 2022: $1,566 · 2023: $1,811 · 2024: $1,515 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,983 · Education: $99.00 · Gift: $0.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,982.58 |
| Education | $99.00 |
| Gift | $0.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,220.27 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,252.58 | 2019-2025 | Injectafer |
| Exeltis, USA INC. | $769.92 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $641.88 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $612.58 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $569.70 | 2019-2025 | |
| Pfizer INC. | $379.02 | 2019-2025 | |
| Astellas Pharma US INC | $357.31 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $356.57 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $273.82 | 2019-2022 | |
| Allergan, INC. | $259.24 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $221.38 | 2023-2025 | Myfembree, Gemtesa |
| Agile Therapeutics, INC. | $189.95 | 2021-2024 | Twirla |
| Myovant Sciences INC. | $174.97 | 2021-2022 | |
| Hologic Sales and Service, LLC | $174.71 | 2022-2025 | Thinprep 2000 Processor, Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $167.90 | 2022-2023 | |
| Sage Therapeutics, LLC | $166.95 | 2024-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $128.49 | 2019 | |
| Duchesnay USA Incorporated | $121.66 | 2019 | |
| Millicent US INC | $104.87 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Exact Sciences Corporation | $101.98 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $72.54 | 2024-2025 | Gardasil 9, Gardasil, Vaqta |
| Shield Therapeutics INC | $70.15 | 2023-2024 | Accrufer |
| Biogen, INC. | $54.47 | 2024-2025 | Zurzuvae |
| Scynexis, INC. | $49.10 | 2022 | |
| Lupin INC. | $42.25 | 2019-2020 | |
| Meditrina | $39.92 | 2024-2025 | |
| Vertical Pharmaceuticals, LLC | $31.78 | 2019 | |
| Becton, Dickinson and Company | $31.47 | 2023 | Bd Onclarity |
| Avion Pharmaceuticals | $30.03 | 2023 | Balcoltra |
| Amgen INC. | $28.68 | 2024 | Prolia, Evenity |
| Alexion Pharmaceuticals, INC. | $25.78 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $20.91 | 2025 | Qelbree |
| Ferring Pharmaceuticals INC. | $20.24 | 2019 | |
| Roche Diagnostics Corporation | $20.08 | 2019 | |
| Medicem INC. | $19.03 | 2021 | |
| Aspira Women'S Health INC | $18.64 | 2023 | Ova1 |
| Avanos Medical | $16.81 | 2020 | |
| Lilly USA, LLC | $16.29 | 2025 | Mounjaro, Zepbound |
| Axonics, INC. | $15.81 | 2024 | Axonics |
| Minerva Surgical, INC | $15.64 | 2024 | |
| Mission Pharmacal Company | $14.84 | 2019 | |
| Channel Medsystems, INC. | $13.47 | 2022-2023 | |
| Mycovia Pharmaceuticals, INC. | $12.97 | 2023 | Vivjoa |
| Endo Pharmaceuticals INC. | $12.61 | 2019 | |
| Covidien LP | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Finke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.